Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3206684 | 0.91 | HTR6 (0.45) | HTR6HTR2CHTR2AMEN1GFER | |
| SCHEMBL3215958 | 0.87 | HTR6 (0.47) | HTR6HTR2CMEN1GFERKMT2A | |
| SCHEMBL3206565 | 0.87 | HTR6 (0.47) | HTR6HTR2CMEN1GFERKMT2A | |
| SCHEMBL3214457 | 0.86 | HTR6 (0.46) | HTR6HTR2CMEN1GFERKMT2A | |
| SCHEMBL3225041 | 0.85 | HTR6 (0.46) | HTR6HTR2C | |
| SCHEMBL3217593 | 0.84 | HTR6 (0.46) | HTR6HTR2CMEN1GFERKMT2A | |
| SCHEMBL3214889 | 0.84 | HTR6 (0.49) | HTR6HTR2CMEN1GFERKMT2A | |
| SCHEMBL3202691 | 0.84 | HTR6 (0.45) | HTR6HTR2CHTR2A | |
| SCHEMBL3623752 | 0.83 | HTR6 (0.64) | HTR6HTR2CHTR2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL3612369 | 0.82 | HTR6 (0.62) | HTR6HTR2CHTR2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | claimed |
| WO-2010024980-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR4, HTR3B | HTR6 1/4885HTR2C 7/4885HTR2A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.